Revolution Medicines (RVMDW) Current Deferred Revenue (2019 - 2023)
Revolution Medicines (RVMDW) posted quarterly Current Deferred Revenue of $1.4 million for Q1 2023, down 87.46% year-over-year from $11.4 million in Q1 2022, and down 67.84% quarter-over-quarter from $4.5 million in Q4 2022.
Revolution Medicines (RVMDW) Current Deferred Revenue (2019 - 2023) Analysis & Trends
Revolution Medicines' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2023.
- In Q1 2023, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million; the TTM figure through Mar 2023 stood at $1.4 million (down 87.46% YoY), while the FY2022 annual figure was $4.5 million, down 63.92% from the prior year.
- Current Deferred Revenue for Q1 2023 stood at $1.4 million, down from $4.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $17.1 million in Q4 2019, with the low at $1.4 million in Q1 2023.
- The 5-year median for Current Deferred Revenue is $11.8 million (2020), against an average of $11.0 million.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue advanced 16.18% in 2022, then slumped 87.46% in 2023.
- Revolution Medicines' Current Deferred Revenue stood at $17.1 million in 2019, then dropped by 29.27% to $12.1 million in 2020, then climbed by 2.04% to $12.4 million in 2021, then slumped by 63.92% to $4.5 million in 2022, then plunged by 67.84% to $1.4 million in 2023.
- Business Quant data shows RVMDW's Current Deferred Revenue at $1.4 million in Q1 2023, $4.5 million in Q4 2022, and $9.7 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.43 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 9.69 Mn |
| Jun 30, 2022 | 9.69 Mn |
| Mar 31, 2022 | 11.43 Mn |
| Dec 31, 2021 | 12.36 Mn |
| Sep 30, 2021 | 12.67 Mn |
| Jun 30, 2021 | 8.34 Mn |
| Mar 31, 2021 | 9.96 Mn |
| Dec 31, 2020 | 12.11 Mn |
| Sep 30, 2020 | 13.11 Mn |
| Jun 30, 2020 | 14.58 Mn |
| Mar 31, 2020 | 16.40 Mn |
| Dec 31, 2019 | 17.12 Mn |